Windtree Therapeutics announced that the Company entered an Exchange and Termination Agreement with affiliates of Deerfield Management Company pursuant to which Deerfield has agreed to terminate its rights under the Company’s 2017 Exchange and Termination Agreement to receive up to $15,000,000 in development and commercial milestone payments associated with AEROSURF, an acute pulmonary drug/device combination intended to treat premature infants with respiratory distress syndrome. Windtree out-licensed global rights to AEROSURF in 2022. In exchange for Deerfield terminating its rights to receive any milestone payments, the Company agreed to issue to Deerfield 608,272 shares of the Company’s common stock and to pay Deerfield a $100,000 cash payment upon execution of the agreement. In addition, the Company agreed to pay Deerfield an additional $100,000 on the earlier of January 24, 2025 or the Company receiving a specified amount of gross proceeds from debt or equity financings occurring on or after the agreement date.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on WINT:
- Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
- Windtree Therapeutics announces license agreement with Lee’s Pharmaceuticals
- Windtree Therapeutics initiated with a Neutral at H.C. Wainwright
- Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
- Windtree Therapeutics announces reduction in arrythmias in istaroxime study